Neuronetics Inc
NASDAQ:STIM
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
US |
Neuronetics Inc
NASDAQ:STIM
|
69.5m USD | -2 | ||
US |
Abbott Laboratories
NYSE:ABT
|
181.9B USD | 38.1 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
141.2B USD | 228.7 | ||
US |
Stryker Corp
NYSE:SYK
|
126.1B USD | 47.1 | ||
IE |
Medtronic PLC
NYSE:MDT
|
112B USD | 26.1 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
109.1B USD | 68.5 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
68.5B USD | 30.7 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
59.7B EUR | 43.9 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
376.2B CNY | 35.7 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
54B USD | 84.1 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
51.4B USD | 87.3 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.